Safety and efficacy of nimotuzumab with concurrent chemoradiotherapy in unresectable locally advanced squamous cell carcinoma of head and neck: An Indian rural hospital experience

CONTEXT: Nimotuzumab is the only anti-epidermal growth factor receptor monoclonal antibody which can be safely added to concurrent chemoradiotherapy (CRT) to improve efficacy in the management of unresectable, locally advanced squamous cell carcinoma of head and neck (LA-SCCHN). However, the evidenc...

Descripción completa

Detalles Bibliográficos
Autores principales: Rawat, Shyamji, Tandan, Hemu, Patel, Sanandan, Chaudhari, Sameer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2019
Materias:
ORIGINAL ARTICLE: Head and Neck Cancers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6348788/
https://www.ncbi.nlm.nih.gov/pubmed/30766856
http://dx.doi.org/10.4103/sajc.sajc_76_18

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6348788/
https://www.ncbi.nlm.nih.gov/pubmed/30766856
http://dx.doi.org/10.4103/sajc.sajc_76_18

Ejemplares similares